Perspective
Split Viewer
Blood Res 2014; 49(3):
Published online September 25, 2014
https://doi.org/10.5045/br.2014.49.3.141
© The Korean Society of Hematology
Is a cure for CML without allogeneic stem cell transplantation around the corner?
Department of Hematology, Kyungpook National University Hospital, Daegu, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- O'Brien, SG, Guilhot, F, Larson, RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 2003;348;994-1004.
- Saglio, G, Kim, DW, Issaragrisil, S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med, 2010;362;2251-2259.
- Kantarjian, HM, Shah, NP, Cortes, JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2012;119;1123-1129.
- Mahon, FX, Rea, D, Guilhot, J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol, 2010;11;1029-1035.
- Ross, DM, Hughes, TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Br J Haematol, 2014;166;3-11.
- Rousselot, P, Charbonnier, A, Cony-Makhoul, P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol, 2014;32;424-430.
- Breccia, M, Alimena, G. Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. Cancer Lett, 2014;347;22-28.
- Thielen, N, van der Holt, B, Cornelissen, JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer, 2013;49;3242-3246.
- Jain, P, Kantarjian, H, Cortes, J. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol, 2013;14;127-143.
PDF
Standard view
Export citation
Share Article
Perspective
Blood Res 2014; 49(3): 141-143
Published online September 25, 2014 https://doi.org/10.5045/br.2014.49.3.141
Copyright © The Korean Society of Hematology.
Is a cure for CML without allogeneic stem cell transplantation around the corner?
Sang Kyun Sohn, M.D.
Department of Hematology, Kyungpook National University Hospital, Daegu, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- O'Brien, SG, Guilhot, F, Larson, RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 2003;348;994-1004.
- Saglio, G, Kim, DW, Issaragrisil, S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med, 2010;362;2251-2259.
- Kantarjian, HM, Shah, NP, Cortes, JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2012;119;1123-1129.
- Mahon, FX, Rea, D, Guilhot, J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol, 2010;11;1029-1035.
- Ross, DM, Hughes, TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Br J Haematol, 2014;166;3-11.
- Rousselot, P, Charbonnier, A, Cony-Makhoul, P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol, 2014;32;424-430.
- Breccia, M, Alimena, G. Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. Cancer Lett, 2014;347;22-28.
- Thielen, N, van der Holt, B, Cornelissen, JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer, 2013;49;3242-3246.
- Jain, P, Kantarjian, H, Cortes, J. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol, 2013;14;127-143.
Previous Article
